*****
似乎有藥片
可滅喘懸浮吸入液0 - AstraZeneca
https://www.astrazeneca.com › Taiwan › Medicines
Pulmicort Respules 0.5mg in 2ml and 1mg in 2ml Nebulising. Suspension for Inhalation. Budesonide 噴霧劑懸浮液。 衛署藥輸字第022050 號. 衛署藥輸字第022049 號. 定性與定量組成：. 每一2ml 之單劑量含有budesonide 0.5 mg 或1mg。
***
地球，人間煉獄 CXXXIX (139th、139期) 0530
The story of mRNA: From a loose idea to a tool that may help ...
https://www.statnews.com › 2020/11/10
2020/11/10 — Scientists have dreamed about the possibilities of custom-made messenger RNA. The pandemic may turn those possibilities into realilty.
Kati Kariko Helped Shield the World From the Coronavirus ...
https://www.nytimes.com › health › c...
2021/04/09 — For her entire career, Dr. Kariko has focused on messenger RNA, or mRNA — the genetic script that carries DNA instructions to each cell's protein-making machinery. She was convinced mRNA could ...
****
広告·https://www.gavi.org/
Gavi, the Vaccine Alliance, supports vaccines against 17 infectious diseases. Gavi helps vaccinate children against deadly and debilitating infectious diseases. Trusted information。
Results & evidence · How our support works · Gavi's mission · Donate
(Reuters) - A commonly used asthma treatment appears to reduce the need for hospitalizations as well as recovery time for COVID-19 patients if given within seven days of symptoms appearing, researchers at the University of Oxford said on Tuesday.
The findings were made following a mid-stage study of the steroid budesonide, sold as Pulmicort by AstraZeneca Plc and also used for treating smoker’s lung.
The 28-day study of 146 patients suggested that inhaled budesonide reduced the risk of urgent care or hospitalization by 90% when compared with usual care, Oxford University said.
Researchers said the trial was inspired by the fact that patients with chronic respiratory disease, who are often prescribed inhaled steroids, were significantly under-represented among hospitalized COVID-19 patients during early days of the pandemic. (bit.ly/3q40g1W)
Initial data from the study also found volunteers treated with budesonide had a quicker resolution of fever and fewer persistent symptoms.
“I am heartened that a relatively safe, widely available and well studied medicine ... could have an impact on the pressures we are experiencing during the pandemic,” said Mona Bafadhel, lead investigator of the trial.
Pulmicort was once a blockbuster drug for coronavirus vaccine-maker AstraZeneca, which now offers a newer medicine, Symbicort, as an alternative asthma treatment.
Results from the Oxford University study are yet to be published in a peer-reviewed journal.
Reporting by Pushkala Aripaka in Bengaluru; Editing by Ramakrishnan M.
Our Standards: The Thomson Reuters Trust Principles.
沒有留言:
張貼留言